Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.
暂无分享,去创建一个
I. Puzanov | M. Milhem | H. Kaufman | O. Hamid | D. Minor | R. Andtbacka | Ai Li | J. Chou